Adverse outcomes and an immunosuppressed endotype in septic patients with reduced IFN-γ ELISpotEvan L. Barrios, Charles C. Caldwell, Mahil Rao et al.|JCI Insight|2023Cited by 21
Determining potential immunomodulatory drug efficacy in sepsis using ELISpotAndrew H. Walton, Richard S. Hotchkiss, Monty B. Mazer et al.|Scientific Reports|2025Cited by 7
Adverse Long-Term Outcomes and an Immune Suppressed Endotype in Sepsis Patients with Reduced Interferon-γ ELISpot: A Multicenter, Prospective Observational StudyEvan A. Barrios, Charles C. Caldwell, Monty B. Mazer et al.|medRxiv|2023Cited by 4